Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 8/20 | 0.60 |
| ▸ | PARP11 | Q9NR21 | 8/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.58 |
| ▸ | PARP1 | P09874 | 7/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3043388 | 0.84 | KDR (0.54) | PARP10PARP11PDE4BKDR | |
| SCHEMBL18170928 | 0.77 | PARP10 (0.55) | PARP10PARP11PDE4BPARP1 | |
| SCHEMBL8301032 | 0.74 | PARP10 (0.51) | PARP10PARP11PDE4BPARP1ACHE | |
| SCHEMBL1746260 | 0.74 | PDE4B (1.00) | PDE4B | |
| SCHEMBL18170862 | 0.73 | KDR (0.56) | PARP10PARP11PDE4BPARP1KDR | |
| SCHEMBL18170525 | 0.72 | MAOA (0.45) | PDE4BPARP1CHEK1 | |
| SCHEMBL18170546 | 0.71 | KDR (0.50) | PARP10PARP11PDE4BKDR | |
| SCHEMBL30701043 | 0.71 | KDR (0.50) | PARP10PARP11PDE4BKDR | |
| SCHEMBL18170563 | 0.70 | KDR (0.61) | KDR | |
| SCHEMBL18170540 | 0.70 | KDR (0.52) | PARP1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856216-B2 | Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2018-01-02 | — | — | US | disclosed |
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-27 | — | — | US | disclosed |
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | TNIK, TNK1, NFKBIA | PARP10 2327/4885PARP11 2557/4885PDE4B 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.